- Home
- NBTX vs RMAX Comparison
NBTX vs RMAX Comparison
Compare NBTX & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- RMAX
- Stock Information
- Founded
- NBTX 2003
- RMAX 1973
- Country
- NBTX France
- RMAX United States
- Employees
- NBTX N/A
- RMAX N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- RMAX Real Estate
- Sector
- NBTX Health Care
- RMAX Finance
- Exchange
- NBTX Nasdaq
- RMAX Nasdaq
- Market Cap
- NBTX 167.8M
- RMAX 151.5M
- IPO Year
- NBTX 2020
- RMAX 2013
- Fundamental
- Price
- NBTX $4.10
- RMAX $7.55
- Analyst Decision
- NBTX Strong Buy
- RMAX Hold
- Analyst Count
- NBTX 1
- RMAX 2
- Target Price
- NBTX $8.00
- RMAX $9.75
- AVG Volume (30 Days)
- NBTX 11.5K
- RMAX 162.4K
- Earning Date
- NBTX 04-02-2025
- RMAX 05-01-2025
- Dividend Yield
- NBTX N/A
- RMAX N/A
- EPS Growth
- NBTX N/A
- RMAX N/A
- EPS
- NBTX N/A
- RMAX 0.44
- Revenue
- NBTX N/A
- RMAX $303,865,000.00
- Revenue This Year
- NBTX N/A
- RMAX N/A
- Revenue Next Year
- NBTX $221.06
- RMAX $1.59
- P/E Ratio
- NBTX N/A
- RMAX $17.24
- Revenue Growth
- NBTX N/A
- RMAX N/A
- 52 Week Low
- NBTX $2.76
- RMAX $6.90
- 52 Week High
- NBTX $7.29
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- NBTX 64.63
- RMAX 47.97
- Support Level
- NBTX $3.64
- RMAX $7.40
- Resistance Level
- NBTX $4.20
- RMAX $7.63
- Average True Range (ATR)
- NBTX 0.16
- RMAX 0.23
- MACD
- NBTX 0.04
- RMAX 0.01
- Stochastic Oscillator
- NBTX 88.51
- RMAX 49.53
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.